GSK reported first-quarter 2026 results that topped analyst estimates, buoyed by strong performance in specialized medicine. Growth in cancer and HIV treatments successfully mitigated declines in the company's general medicines division.
- Q1 2026 financials beat analyst expectations
- HIV and cancer drug sales provided critical growth